Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating

The Relative Strength (RS) Rating for Axsome Therapeutics jumped into a new percentile Wednesday, with an increase from 72 to 81.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This unique rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes.

Decades of market research shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Axsome Therapeutics is trying to complete a consolidation with a 91.29 entry. It rebounded above the 200-day moving average and is now trying to clear the rest. If the stock does that, then let's see if it can break out in heavy trading and clear the pivot.

The company posted 0% earnings growth in the latest quarterly report. Sales increased 429%.

Axsome Therapeutics holds the No. 156 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm and HUTCHMED (China) ADR are also among the group's highest-rated stocks.

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.